Urine Pneumococcal Antigen Project

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12-24
SponsorLiverpool School of Tropical Medicine

About this trial

Background:

Pneumonia caused by the bacteria Streptococcus pneumoniae is a leading cause of death among children under five years of age, especially in sub-Saharan Africa. Accurate diagnosis remains challenging due to the need for invasive procedures to obtain samples for culture-based diagnostic tests, which are not very sensitive for detecting S.pneumoniae, particularly after antibiotic use.

Serotype-specific urinary antigen detection (ssUAD) assays are a promising, non-invasive alternative for the surveillance and diagnosis of pneumococcal disease. Importantly, they can identify different serotypes of S.pneumoniae, which is crucial for monitoring vaccine impact. However, the ability of the ssUAD to identify invasive disease due to S.pneumoniae has not been studied in children in sub-Saharan Africa, where high rates of asymptomatic carriage may affect diagnostic accuracy.

Aim:

The overall aim of this study is to evaluate the performance of the ssUAD test to detect pneumococcal carriage, and distinguish it from invasive disease, among children under five years old in Blantyre, Malawi.

Methods:

This study will test 350 existing urine samples that have already been collected from children as part of the NP Resistome study (LSTM reference 24-076), including healthy children in the community, children with pneumonia in the community, and children hospitalised with pneumonia. Participants of the NP Resistome study will be recruited from Ndirande Health Centre (NHC), Gateway Primary Care Centre (GPCC) and Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi. Aliquots from each urine sample will be tested using the ssUAD in the UK, as the assay is not currently available in Malawi. Urinary detection of pneumococcal serotypes will be compared with both culture-based and metagenomic sequencing results from nasopharyngeal swab samples taken as part of the main study.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

Presence of any of the following symptoms: fever, cough, difficulty in breathing or fast breathing.

Currently taking long-term antibiotic prophylaxis, TB treatment or immunosuppressive medications.

Diagnosis of an immunosuppressive illness, including HIV infection.

Hospital admission within the past six months.

Trial population

Participants will be children aged 12-24 months enrolled in the NP Resistome study (COMREC reference P.10/24-1200) in the following groups; * Children hospitalised with pneumonia at Queen Elizabeth Central Hospital. * Children with pneumonia treated at Ndirande Health Centre. * Healthy children living in Ndirande community.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

350 Participants
are grouped into 4 trial groups
Group A: Healthy community
Group B: Community pneumonia
Group C: Hospital pneumonia - first admission
Group D: Hospital pneumonia - re-admission

Trial outcomes

Primary outcomes

1

Number of participants with serotype-specific urinary pneumococcal antigen detected

Number of participants with serotype-specific pneumococcal antigen detected in urine samples taken at recruitment, using an extended-specificity multiplex urine immunoassay.

Time frame
At the time of recruitment/participant enrolment.

Secondary outcomes

1

Number of participants with nasopharyngeal carriage of Streptococcus pneumoniae (detected based on culture)

Detection of Streptococcus pneumoniae following culture of nasopharyngeal swab samples from participants on Sheep Blood Agar with 5 µg/mL of Gentamicin (GBA).

Time frame
At time of recruitment/enrolment.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Liverpool School of Tropical Medicine

Lead sponsor

Malawi Liverpool Wellcome Programme

Collaborator